Disease System Analysis: Basic Disease Progression Models in Degenerative Disease
暂无分享,去创建一个
Meindert Danhof | J. DeJongh | T. Post | M. Danhof | J. Freijer | Joost DeJongh | Teun M. Post | Jan I. Freijer | Jan I. Freijer
[1] M Danhof,et al. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[2] L. Peletier,et al. Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan. , 2002, European journal of pharmacology.
[3] C C Peck,et al. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[4] Robert C. Wolpert,et al. A Review of the , 1985 .
[5] Jean-Pierre Devogelaer,et al. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. , 2004, Osteoarthritis and cartilage.
[6] W J Jusko,et al. Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.
[7] C. Olanow,et al. The scientific basis for the current treatment of Parkinson's disease. , 2004, Annual review of medicine.
[8] K E Peace,et al. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] L. Sheiner. Is intent-to-treat analysis always (ever) enough? , 2002, British journal of clinical pharmacology.
[10] Malcolm Rowland,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2004, Pharmaceutical Research.
[11] L. Peletier,et al. Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.
[12] P. Jenner,et al. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease , 2002, Neurology.
[13] Bruce R. Brodie,et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial , 2004 .
[14] M. Guttman,et al. Dopamine agonist monotherapy in Parkinson's disease , 2002, The Lancet.
[15] R. Lavielle,et al. The mode of action and clinical pharmacology of gliclazide: a review. , 1991, Diabetes research and clinical practice.
[16] D. Rubin,et al. Intention‐to‐treat analysis and the goals of clinical trials , 1995, Clinical pharmacology and therapeutics.
[17] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.
[18] J. Brotchie,et al. Drugs in development for Parkinson's disease. , 2004, Current opinion in investigational drugs.
[19] E Niclas Jonsson,et al. More efficient clinical trials through use of scientific model‐based statistical tests , 2002, Clinical pharmacology and therapeutics.
[20] L. V. D. van de Putte,et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. , 1997, British journal of rheumatology.
[21] W J Jusko,et al. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.
[22] P. Lipsky,et al. Infliximab in active early rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[23] Johan Gabrielsson,et al. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .
[24] N. Holford,et al. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. , 2003, British journal of clinical pharmacology.
[25] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[26] Timothy Goggin,et al. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. , 2004, British journal of clinical pharmacology.
[27] K. Johnson. An Update. , 1984, Journal of food protection.
[28] L. Peletier,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. , 2002, The Journal of pharmacology and experimental therapeutics.
[29] W. Colburn,et al. Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing , 2003, Journal of clinical pharmacology.
[30] K E Peace,et al. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[32] P. Jenner. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease , 2003, Current opinion in neurology.
[33] L. Lesko,et al. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.
[34] E. Bock,et al. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate , 1999, Annals of the rheumatic diseases.
[35] Carlos R Plata-Salamán,et al. Biomarker discovery and validation: technologies and integrative approaches. , 2004, Trends in biotechnology.
[36] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[37] W. Colburn,et al. Biomarkers, Validation and Pharmacokinetic-Pharmacodynamic Modelling , 2003, Clinical pharmacokinetics.
[38] F E Shaffer,et al. Elusive Goal , 1979, Science.
[39] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[40] Mechanism-Based Modeling of the Pharmacodynamic Interaction of Alphaxalone and Midazolam in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.
[41] B. Månsson,et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept , 2003, Arthritis research & therapy.
[42] K. Peace,et al. The effect of tacrine and lecithin in Alzheimer's disease , 2004, European Journal of Clinical Pharmacology.
[43] Meindert Danhof,et al. A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. , 2002, The Journal of pharmacology and experimental therapeutics.
[44] L. Lesko,et al. Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.
[45] W. Jusko,et al. Characterization of four basic models of indirect pharmacodynamic responses , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[46] N H Holford,et al. Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.
[47] P H van der Graaf,et al. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[48] A. Stoessl,et al. New concepts and tools in imaging for the study of neurodegenerative disease. , 2003, Journal of neural transmission. Supplementum.
[49] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[50] P. Richette,et al. Structure-modifying agents for osteoarthritis: an update. , 2004, Joint, bone, spine : revue du rhumatisme.
[51] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[52] B. Ravina,et al. Neuroprotection in Parkinson's Disease: An Elusive Goal , 2007, Seminars in neurology.